Kornimate/medical-research-clean huggingface dataset:
pro-active genetic testing in patients with solid tumors, inherit study

Conditions: Breast Carcinoma; Digestive System Neoplasm; Malignant Brain Neoplasm; Malignant Central Nervous System Neoplasm; Malignant Female Reproductive System Neoplasm; Malignant Genitourinary System Neoplasm; Malignant Head and Neck Neoplasm; Malignant Musculoskeletal Neoplasm; Malignant Solid Neoplasm; Metastatic Malignant Neoplasm of Unknown Primary; Skin Carcinoma

Summary: this phase i trial collects blood samples to investigate the prevalence of changes in genes (genetic mutations) in solid tumor patient populations seeking care at mayo clinic embedded cancer center at st. vincent's riverside. this may help doctors better understand and/or treat others who have genetic mutations.

primary objective: i. to determine the prevalence of genetic mutations in cancer patients seeking care at the mayo clinic cancer center at st. vincent's riverside in jacksonville, florida. secondary objectives: i. perform a chart review to assess the impact of genetic testing as part of standard of oncology care: ia. determine differences in germline mutation detection in these patients as compared to traditional guideline (national comprehensive cancer network \[nccn\]) based approach for genetic evaluation. ib. determine the percentage of relatives of mutation positive probands undergoing family variant testing within a 3 month window of return of testing results. ic. assess patient experience and barriers to care with a genetic service line via survey measures. id. develop a biorepository of samples (blood) from cancer patients participating in this protocol. outline: patients watch a pre-recorded genetic counseling video and those who consent to genetic testing undergo collection of blood samples. patients also complete surveys over 5-15 minutes each prior to receiving their genetic test results and following the receipt of genetic test results.

Eligibility criteria:
inclusion criteria: * individuals diagnosed with any solid tumor cancer (stages 1-4) including, but not limited to, gastrointestinal, breast, gynecological, genitourinary, skin, central nervous system (cns)/brain, head/neck, musculoskeletal or cancer of unknown primary * blood collection is feasible (health, access and/or tolerability) for requested blood sample(s) * individuals have agreed to participate and signed the study informed consent form exclusion criteria: * individuals who do not meet study inclusion criteria * individuals with an active hematologic malignancy * patients who have had prior germline genetic testing involving a 40+ gene panel within the last 24 months at mayo clinic or st vincent's healthcare and available for review by the research coordinator at time of consent
a comparison of laparoscopic cholecystectomy versus ultrasonic dissection assisted minilaparotomy cholecystectomy

Conditions: Postoperative Pain

Summary: minilaparatomy cholecystectomy with ultrasonic dissection (usd) is rarely considered and therefore we investigate here the contributions of usd in early recovery.


Eligibility criteria:
inclusion criteria:- uncomplicted symptomatic cholelithiasis cholecystitis confirmed by ultrasoud * asa physical status 1-3 * body mass index 18-30 * age 18 - 75 years exclusion criteria: * pregnancy or lactating * common bile-duct stones * acute cholecystitis * previous upper abdominal operation * chirrosis * renal disease * pancreatitis * asa 4-5 * participation of any other clinical trial within 30 days before the start of the screening period * history of uncontrolled cardiovascular, epileptic disorder, psychosis.

Keywords: cholecystectomy,minilaparotomy,laparascopy,ultrasonic dissection
an evaluation of root length measurements using intraoral scan and panoramic radiographs

Conditions: Root Resorption

Summary: this study will attempt to validate a method of estimating root length on panoramic radiograph by crown measurement on intraoral digital scans.

intraoral digital scans will be taken on patients who have completed orthodontic treatment, and measurements will be made on the crown dimensions. these dimensions will then be applied onto the same teeth as seen on panoramic radiographs and a mathematical relationship will be determined for root length. changes in root length will be measured from initial records to treatment complete panoramic radiographs and these estimates will be compared to actual root length changes as measured in cbct (cone beam computed tomography) records.

Eligibility criteria:
inclusion criteria: * subject has initial records including cbct scan and panoramic radiograph that are clear. subject must have no restorations or significant loss in tooth structure in target teeth or teeth adjacent to target. exclusion criteria: * subjects who have records that are not clear, and who are missing target teeth.

Keywords: root resorption panoramic radiograph
medtronic minimed implantable insulin pump

Conditions: Type 1 Diabetes

Summary: this research is being done to find out whether subjects previously treated with the implantable insulin pump (iip) therapy, and now taking insulin by injection, will benefit from re-implantation of iip. the investigators will see if iip causes more stable control of blood sugar, with fewer highs and lows. people with type 1 diabetes previously implanted with the minimed implantable pump (mip) model 2000 at johns hopkins may join this study.

if the participant joins the study and chooses to have a new pump implanted, the study is expected to last 12-15 months for each participant, and each participant will continue to be followed, with 3-monthly refills and research visits for as long as the pump lasts, until the participant chooses to withdraw, until the fda approves the pump for regular care, or until the company stops supporting the pump. during the first 12-15 months of the study, there will be an estimated 13 clinic visits and one hospital stay for 2-3 days. the data collection visits will take about 30 minutes, and a continuous glucose monitor will be started. the participants will have a brief visit 3-4 days later to drop off the monitor. after this phase of the research, the participants will still be cared for with the implanted pump, having visits for refills and tests every 3 months. this long-term follow up will last until the participants choose to withdraw, the pump malfunctions, the fda approves the pump for regular care, or the company no longer supports the pump. if the participants are no longer taking part in the study, the investigators will have the pump removed from their body.

Eligibility criteria:
inclusion criteria: * people with type 1 diabetes previously implanted with the minimed implantable pump model 2000 at johns hopkins may join this study. exclusion criteria: * anyone not previously implanted with the minimed implantable pump model 2000 at johns hopkins.
immune response to intranasal influenza vaccination

Conditions: Tonsillitis, Hypertrophy

Summary: this research during the last decade has focused on the kinetics of the systemic and local immune response to parenteral influenza vaccine in humans. the investigators have shown that normally high numbers of influenza specific antibody secreting cells (asc) are present in the nasal mucosa of healthy adults but upon parenteral vaccination the numbers remain stable. however, a rapid transient increase in specific asc is observed in the tonsils and peripheral blood after parenteral vaccination. in the tonsils, this is associated with a significant decrease in both naïve/effector (cd45ra+) and memory (cd45ro+) cd4+ cells upon vaccination. in this study the investigators will extend our work to investigate the characteristics of influenza-specific t- and b-cells induced locally and systemically after intranasal vaccination in man.

the clinical trial will be an open study. all subjects eligible for tonsillectomy at haukeland university hospital within the specified age range (children: 2 to less than 18 years old and adults \>18-59 years old) will receive an invitation to join the study. the primary endpoints of the trial are the evaluation of the systemic and local immune response after live attenuated influenza vaccine. the vaccine specific immune response will be assessed through the induction of specific local and systemic antibody and cellular immune responses, and analyses of the epitopes to which the response is directed. furthermore the capacity of the vaccine to elicit cross reactive and long lasting immunity will be evaluated.

Eligibility criteria:
inclusion criteria: * healthy children (age range ≥2 and \ 18-59 years old) as concluded from the medical history, physical examination, and clinical judgment) scheduled for tonsillectomy ; * signed informed consent from the subject or both parents/ both guardians and from subjects aged 12 years and older; * subjects or guardians able to understand and comply with the study protocol and complete the adverse event form: * subjects able to attend the scheduled visits. exclusion criteria: * persons with a history of anaphylaxis or serious reactions to any vaccine; * person with known hypersensitivity to any of the vaccine components (e.g. gelatin, gentamicin, eggs or egg proteins (e.g. ovalbumin); * persons who are pregnant * persons who have had a temperature \>38oc during the previous 72 hours; * persons who have had an acute respiratory infection during the last 7 days; * persons who are clinically immunodeficient due to conditions or immunosuppressive therapy such as: acute and chronic leukaemias; lymphoma; symptomatic hiv infection; cellular immune deficiencies; and high-dose corticosteroids; * persons with severely immunocompromised family members; * persons with severe asthma or active wheezing.

Keywords: influenza, laiv, immune response
a research study to see how well cagrisema compared to semaglutide, cagrilintide and placebo lowers blood sugar and body weight in people with type 2 diabetes treated with metformin with or without an sglt2 inhibitor

Conditions: Type 2 Diabetes Mellitus

Summary: the study will look at how well cagrisema helps people lower their blood sugar and body weight. cagrisema is a new weekly medicine that combines two medicines called semaglutide and cagrilintide. cagrisema will be compared to the two medicines semaglutide and cagrilintide, when they are taken alone. cagrisema will also be compared to a "dummy" medicine without any active ingredient. the study will be done in participants who have type 2 diabetes. participants will take the study medicine together with the current diabetes medicine (metformin with or without an sglt2 inhibitor).


Eligibility criteria:
inclusion criteria: * male or female (sex at birth). * age 18 years or above at the time of signing the informed consent. * diagnosed with type 2 diabetes mellitus greater than or equal to 180 days before screening. * stable daily dose(s) greater than or equal to 90 days before screening of any of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator: metformin with or without sodium-glucose cotransporter-2 (sglt2) inhibitors. * glycated haemoglobin (hba1c) 7.0-10.5 percent (53-91 millimoles per mole \[mmol/mol\]) (both inclusive) as determined by central laboratory at screening. * body mass index (bmi) greater than or equal to 25 kilogram per square metre ( kg/m\^2) at screening. bmi will be calculated in the electronic case report form (ecrf) based on height and body weight at screening. exclusion criteria: * renal impairment with estimated glomerular filtration rate (egfr) less than 30 milliliters per minute per 1.73 square metre (ml/min/1.73 m\^2) as determined by central laboratory at screening. * treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. however, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed. * uncontrolled and potentially unstable diabetic retinopathy or maculopathy. verified by an eye examination performed within 90 days before screening or in the period between screening and randomisation.
effects of tudca on endothelial function in type 2 dm

Conditions: Diabetes Mellitus, Type 2; Insulin Response; Endothelial Dysfunction

Summary: the pilot study is designed to investigate the acute and chronic effects of the diet supplement tauroursodeoxycholic acid (tudca) on endothelial function in participants with type 2 diabetes mellitus.

this is a pilot study designed to investigate the effect of two doses of tudca on endothelial function.all subjects will receive 500 mg/day in a one week run-in period and then 1750 mg/day in one week treatment period. the study will consist of four visits (screening visit and three study visits), and last up to 2 weeks for individual subjects, depending on the time between visits. it is estimated that the study will last two years from irb approval through data analysis.

Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus defined as fasting glucose greater than or equal to 120 mg/dl, hga1c ≥6.5% or ongoing treatment with hypoglycemic medication. * willing to give written informed consent and able to understand, to participate in and to comply with the study requirements. exclusion criteria: * women lactating or pregnant. all women with childbearing potential will undergo a urine pregnancy test at each visit to exclude pregnancy. * treatment with an investigational product within the last 30 days. * clinically evident major illness of other organ systems, including end-stage cancer, renal failure, or other conditions that in the opinion of the principal investigator make a clinical study inappropriate. * inability to provide informed consent. * clinical instability that would preclude withholding medications as determined by the study physician.

Keywords: tauroursodeoxycholic acid (tudca) endothelial function in humans endoplasmic reticulum stress
evaluation of a tailored virtual intervention to empower persons living with hiv for therapy self-management

Conditions: HIV

Summary: the purpose of this study is to evaluate the efficacy of an online virtual intervention in optimizing adherence to antiretroviral medication intake among persons living with hiv (plhiv).


Eligibility criteria:
inclusion criteria: * have to be under art for at least six months¸ * have internet access exclusion criteria: * be pregnant * active iv drug user * actual diagnosis of psychiatric health problem

Keywords: adherence hiv antiretroviral therapy tailored web intervention
the potential role of srage, kl-6, and sp-d as prognostic factors in children with covid-19

Conditions: SARS CoV 2 Infection; Alveolar; Injury; Children; Pneumonia, Viral

Summary: covid-19 causes a wide spectrum of clinical illness, from upper respiratory symptoms to severe respiratory failure and death. several plasma biomarkers -such as il-6, c-reactive protein (crp), d-dimer, the neutrophil-to-lymphocyte ratio, and ferritin, among others- have been studied as markers of disease severity and prognosis. besides, as alveolar damage biomarkers such as surfactant protein d (sp-d), krebs von den lungen-6 (kl-6), and soluble receptor for advanced glycation end products (srage) can be used in lung diseases as well as covid-19 pneumonia. the investigators hypothesized that serum sp-d, kl-6 and srage levels increases in the setting of covid-19 pneumonia. in this prospective study the investigators aimed to determine the clinical value of serum kl-6, sp-d and srage levels as a prognostic marker in children with covid-19 patients. in the literature review, it has been determined that there is no study conducted or published in pediatric patients for this purpose, and it is aimed that our study will be a pioneer study on this subject.

it aimed to determine the clinical value of serum kl-6, sp-d and srage levels as a prognostic marker in children with covid-19 patients.. this study was planned as a case-control study with patients hospitalized in the haseki training and research hospital pediatric infection ward. a total of 150 children, including at least 30 patients in each group were included in the study. the study group was divided into three groups according to covid-19 who clinical progression scale: uninfected (group 1), mild (group 2) and moderate (group 3). in order to investigate the relationship between disease severity and alveolar damage, serum kl-6, sp-d and srage levels and high sensitive c-reactive protein were measured. these biomarkers levels were compared between three groups.

Eligibility criteria:
inclusion criteria: 1. between 1 month-18 years old 2. sars-cov-2 pcr positive 3. not having a chronic disease (cystic fibrosis, etc.) 4. volunteering to participate in the study 5. healty control exclusion criteria: 1. having a chronic disease 2. patients who could not be diagnosed with sars-cov-2 infection by laboratory and/or radiological examinations 3. not volunteering to participate in the stud

Keywords: soluble receptor for advanced glycation end products krebs von den lungen-6 surfactant protein d children sars cov 2 infection pneumonia
safety and efficacy evaluation of ultherapy™ system in aging hand

Conditions: Wrinkles

Summary: enrolled subjects will receive ultherapy™ system treatment on the back of their both hands. follow-up visits will occur at 90 days post-treatment. study photos will be obtained pre-treatment and at 90 days post-treatment

before treatment: the subject's eligibility (inclusion/exclusion criteria) will be assessed, and the 5-point hand grading scale wil be evaluated by the investigator in charge of assessment. treatment: the investigator will apply to the eligible subject the study device ultherapy™ system with 20 lines of 1.5 and 3.0 probe respectively to the back of the left and right hand . post-treatment: all subjects will visit the institution at12 weeks from the day of procedure, and will take photos of the back of the hands. efficacy evaluation will performed by the photographic evaluator.

Eligibility criteria:
inclusion criteria: * male or female, aged 30 to 65 years. * score of 1 to 3 on the 5-point hand grading scale * subjects who understand the study contents and signed the informed consent exclusion criteria: * presence of an active systemic infectious disease * significant scarring in the hand to be treated * previous episode of surgery in the hand to be treated * subjects who have aesthetic addiction, drug abuse, alcohol abuse

Keywords: skin laxity ultherapy™ system rhytids
effect of complementary and alternative medicine on pain among inpatients

Conditions: Pain

Summary: the proposed study has 3 aims: 1) quantitatively describe a model for delivering complementary and alternative medicine (cam) therapies to understand the selection of patients and cam therapies used for pain management, 2) examine the effects of selected cam therapies on immediate change in pain, and 3) examine the effects of selected cam therapies on duration of pain change. positive results from this study will assist hospitals in the integration of usual care and cam therapy for pain reduction. findings may also drive future research on the cost effectiveness of these therapies for pain management, as well as the impact on patient outcomes such as length of stay and use of narcotics.


Eligibility criteria:
aims 1 and 2 inclusion criteria: * admission to abbott northwestern hospital * consent to release of electronic health record for research purposes * 18 years of age or older * length of stay greater than 24 hours aims 1 and 2 exclusion criteria: * none aim 3 inclusion criteria: * admission to abbott northwestern hospital * length of stay greater than 24 hours * 18 years of age or older * consent to release of electronic health record for research purposes * received cam therapy in current hospitalization * pain level of 1 or greater at the pre-treatment assessment by practitioner * english-speaking * integrative medicine therapy ended between 9:00 am and 4:00 pm aim 3 exclusion criteria: * refuses consent * unable to provide consent due to competency concerns * has declined study participation 3 times during current hospitalization * has hard declined during current hospitalization * has been approached 6 times during current hospitalization * has been approached to consent earlier that day

Keywords: complementary and alternative medicine integrative medicine pain management
a non-interventional safety study of balsamic bactrim

Conditions: Bronchitis

Summary: this is a pilot, observational and multicentric study of safety of sulfamethoxazole + trimethoprim + guaifenesin (balsamic bactrim) in adult participants with acute bronchitis. adult participants with acute bronchitis eligible for treatment with balsamic bactrim will be enrolled. administration of balsamic bactrim will be according to physician's recommendation under local labeling.


Eligibility criteria:
inclusion criteria: * participants starting treatment with balsamic bactrim as per treating physician's discretion * participants with a clinical diagnosis of acute bronchitis (cough with or without sputum production less than 30 days) according to the treating physician's judgment exclusion criteria: * participants who have started treatment with another antibiotic at the time of the visit * participants with no respiratory infections * participants with mental disorders that do not permit the clinical evaluation of the participant according to the treating physician's criteria * participants with severe hepatic parenchymal damage * participants with severe renal failure making it difficult to monitor drug plasma concentration * participants with hypersensitivity to any of balsamic bactrim active ingredients, excipients, and/or sulfas
oxycodone extended-release in the treatment of perioperative pain in patients undergoing orthopaedic surgery

Conditions: Surgery

Summary: inadequate control of acute postoperative pain (dapo) brings deleterious consequences for the patient, including significant cardiovascular and respiratory complications. apart from the human suffering that is undeniable pain. schemes oral analgesia with opioids for the treatment of dapo, have shown to be as or more effective than intravenous or epidural regimes, and less expensive. comparing the effectiveness of 10 to 20 mgs of oxycodone sustained release for 12 hours before surgery, into two groups of 20 patients (o-10, o-20) undergoing orthopedic surgery, in a scheme involving multimodal ketoprofen, dipyrone metoclopramide and dexamethasone. values were recorded visual analog scale (vas)for pain at rest and effort, requirement for rescue intravenous morphine and incidence of side effects to the entry and exit of the pacu (t0, te) and at 6 and 18 hours postoperatively (t6, t18),and patient satisfaction.


Eligibility criteria:
inclusion criteria: * asa i and ii patients between 18 and 60 years old, both sexes, undergoing elective orthopedic surgery. exclusion criteria: * use of psychotropic medication or illicit drug use * pregnancy * liver disease * opioid use * history of postoperative nausea and vomiting * ileus * allergy or intolerance to any of the study drugs * physical or mental inability to use the pain scale, or any surgical complications.

Keywords: postoperatory pain oxycodone